Stockscreener 앱 받기
1.75
0.57%
-0.01
시간 외 거래:
1.77
0.02
+1.14%
Aileron Therapeutics Inc 주식(ALRN)의 최신 뉴스
Aileron Therapeutics to Present at the 8th Annual IPF Summit - The Eastern Progress Online
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock By Investing.com - Investing.com Nigeria
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock - Investing.com
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - The Eastern Progress Online
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - MarketBeat
Aileron Therapeutics Reports Q3 2024 Financial Results - MSN
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat
Aileron Therapeutics Inc (ALRN) Quarterly 10-Q Report - Quartzy
Aileron Reports Positive Phase 1b Data for IPF Drug, Shows Strong Biomarker Response | ALRN Stock News - StockTitan
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis - AOL
Aileron reports promising phase 1b trial results for IPF treatment - Investing.com
Aileron reports promising phase 1b trial results for IPF treatment By Investing.com - Investing.com UK
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - Nasdaq
Advancium explores ALRN-6924 for pediatric eye cancer treatment - Investing.com India
Advancium explores ALRN-6924 for pediatric eye cancer treatment By Investing.com - Investing.com Canada
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - PR Newswire
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 14.2% - MarketBeat
Constrained Peptide Drugs Market Size, Scope and Share Analysis - InsightAce Analytic
Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Increases By 15.8% - MarketBeat
ALRNAileron Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis - Lelezard
University of Texas Texas AM Investment Management Co. Invests $4.93 Million in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Nantahala Capital Management LLC Raises Holdings in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - MarketBeat
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 13.4% in September - MarketBeat
Alumis (NASDAQ:ALMS) Trading 4.8% Higher - MarketBeat
Keeping an Eye on Alx Oncology Holdings Inc (ALXO) After Insider Trading Activity - Knox Daily
Ready to Jump After Recent Trade: Alx Oncology Holdings Inc (ALXO) - SETE News
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat
Market Highlights: Alector Inc (ALEC) Ends on a Low Note at 5.45 - The Dwinnex
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Keith Johns Joins Allurion's Board Of Directors - MPO-mag
HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
Healius sells Lumus imaging unit to Affinity for USD 657M - Medical Buyer
Australia Medical Diagnostics Firm Healius Sells Lumus to Affinity for $657 Million - BNN Bloomberg
Renaissance Technologies LLC Sells 800 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World
Alector (NASDAQ:ALEC) Stock Price Up 9% - Defense World
1,959,896 Shares in Alumis Inc. (NASDAQ:ALMS) Bought by SR One Capital Management LP - MarketBeat
Aileron Therapeutics Inc Inc. (ALRN) Price Performance: The Role of Supply and Demand - The InvestChronicle
Closing Bell Recap: Aileron Therapeutics Inc (ALRN) Ends at 2.91, Reflecting a 9.81 Upturn - The Dwinnex
Altair Engineering: Rating Downgrade As Near-Term Upside Is Limited (NASDAQ:ALTR) - Seeking Alpha
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alesi Surgical wins FDA clearance for smoke management device and lands new funding - Mass Device
2.88%
2.65%
자본화:
|
볼륨(24시간):